Navigation Links
Although Remicade and Humira Are Being Increasingly Prescribed for Crohn's Disease and Ulcerative Colitis, Insurers Are Subjecting Both Drugs to Multiple Cost-Control Strategies
Date:3/4/2008

Nearly One-Third of Surveyed Managed Care Organizations Levy Coinsurance Charges and Other Protocols on Remicade and Humira, According to a New

Report from Decision Resources

WALTHAM, Mass., March 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although gastroenterologists are increasingly prescribing Centocor/Schering-Plough/Mitsubishi Tanabe's Remicade and Abbott/Eisai's Humira for the treatment of Crohn's disease and ulcerative colitis, a high proportion of managed care organizations (MCOs) subject both drugs to multiple cost-control strategies to keep costs down and limit the use of the two biologic therapies.

The new Physician & Payer Forum primary market research report entitled The Emergence of New Biologic Treatment Options for Crohn's Disease and Ulcerative Colitis: Physician and Payer Attitudes includes forecasts on the future of biological therapy in the treatment of Crohn's disease and ulcerative colitis, based on the views of prescribers and MCO pharmacy directors. According to the report, nearly one-third of the 20 MCOs surveyed levy coinsurance charges on Remicade and Humira and most plans require prior authorization for each drug. More than half of the plans that cover both drugs also employ step-therapy protocols. The report also finds that six of the 20 MCOs surveyed plan to extend their step therapy requirements during 2008 for Remicade, and five of 19 MCOs will do the same for Humira.

"Despite prior authorization and step therapy protocols that MCOs have put into place, both Remicade and Humira are being increasingly prescribed to patients with Crohn's disease," said Cindy Mundy, Ph.D. director at Decision Resources. "Humira, which was approved for Crohn's disease in January, 2007, is rapidly gaining ground on Remicade in terms of physician perceptions of key measures. We also found that approximately half of surveyed gastroenterologists consider the two drugs to be equal in treating Crohn's disease."

The Emergence of New Biologic Treatment Options for Crohn's Disease and Ulcerative Colitis: Physician and Payer Attitudes is based on a U.S. survey of 101 gastroenterologists and 20 managed care organization pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

About Physician & Payer Forum

Physician & Payer Forum is a primary research service from Decision Resources that offers access to high volume-prescribing physicians, specialists, and managed care organization representatives in the United States; analysis of events and survey participants' responses to them; insight into prescribing patterns; and an examination of the implications of events and issues for the pharmaceutical market.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
2. Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
3. Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab)
4. Abbotts HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care
5. Video: YMCAs Commit to Helping Americans Keep Their New Years Resolutions in Support of Health and Well-Being
6. K-State Trauma Researcher Says Being Prepared, Taking Action Are Vital in Preventing Tragedies Like the One at NIU
7. French paradox redux? US vs. French on being full
8. Select Comfort Creates Sleep Number Quality of Life Advisory Board to Improve Lives, Enhance Well-Being
9. Smart Home Cleaning: New Web Site Educates Consumers on Looking Clean Versus Being Clean
10. UM/Sylvester Offers Community the Gift of Well Being
11. Consumers Being Misled Over Bioavailabity of Resveratrol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
(Date:6/24/2016)... ... 2016 , ... People across the U.S. are sharpening their pencils and honing ... contest in which patients and their families pay tribute to a genetic counselor by ... Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) sponsors ... on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, ... to helping service members that have been wounded in battle and their families. Venture ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia ... the company,s second affiliate in Latin America . ... ... Farma Colombia ... ...
Breaking Medicine Technology: